v3.25.2
Segments (Tables)
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Forth Disaggregated Research and Development Expenses

In addition to the significant expense categories included within net loss presented on the unaudited condensed consolidated statements of operations and comprehensive loss, the following table sets forth disaggregated research and development expenses (in thousands):

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Direct research and development expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Budoprutug

 

$

4,521

 

 

$

42

 

 

$

10,662

 

 

$

42

 

CLYM1161

 

 

145

 

 

 

—

 

 

 

9,265

 

 

 

—

 

Legacy programs2

 

 

31

 

 

 

33

 

 

 

73

 

 

 

107

 

Unallocated research and development expenses:

 

 

 

 

 

 

 

 

—

 

 

 

—

 

Personnel-related (including stock-based compensation)

 

 

1,452

 

 

 

882

 

 

 

3,209

 

 

 

1,825

 

Other research and development expenses

 

 

426

 

 

 

89

 

 

 

693

 

 

 

163

 

Total research and development expenses

 

$

6,575

 

 

$

1,046

 

 

$

23,902

 

 

$

2,137

 

 

1 Includes the upfront payment and the associated direct transaction costs incurred in connection with the Mabworks Agreement for the six months ended June 30, 2025.

2 Includes direct expenses related to the Company's legacy product candidates ETX-123 and ETX-155.